Beernaert B, Parkes EE (2023) CGAS-STING signalling in cancer: striking a balance with chromosomal instability. Biochem Soc Trans 51(2):539–555

Beg S et al (2011) Dendrimers as novel systems for delivery of neuropharmaceuticals to the brain. CNS Neurol Disord-Drug Targets 10(5):576–588

Berger G, Marloye M, Lawler SE (2019) Pharmacological modulation of the STING pathway for cancer immunotherapy. Trends Mol Med 25(5):412–427

Bordon Y (2021) Mutant p53 chills tumours by turning off cGAS. Nat Rev Immunol 21(3):134–135

Bose D (2017) CGAS/STING pathway in cancer: Jekyll and hyde story of cancer immune response. Int J Mol Sci 18(11):2456

Boyd LNC et al (2022) Heterogeneity and plasticity of cancer-associated fibroblasts in the pancreatic tumor microenvironment. Semin Cancer Biol 82:184–196

Buzea C, Pacheco I (2018) Toxicity of nanoparticles, in nanotechnology in eco-efficient construction: materials, processes and applications 705–754

Cai H et al (2020) IFI16 promotes cervical cancer progression by upregulating PD-L1 in immunomicroenvironment through STING-TBK1-NF-kB pathway. Biomed Pharmacother 123:109790

Cao L et al (2022) Activating cGAS-STING pathway with ROS-responsive nanoparticles delivering a hybrid prodrug for enhanced chemo-immunotherapy. Biomater 290:121856

Cao L et al (2022) Activating cGAS-STING pathway with ROS-responsive nanoparticles delivering a hybrid prodrug for enhanced chemo-immunotherapy. Biomaterials 290:121856

Carter JM et al (2021) Characteristics and spatially defined immune (micro)landscapes of early-stage PD-L1–positive triple-negative breast cancer. Clin Cancer Res 27(20):5628–5637

Chattopadhyay S et al (2020) Synthetic immunogenic cell death mediated by intracellular delivery of STING agonist nanoshells enhances anticancer chemo-immunotherapy. Nano Lett 20(4):2246–2256

Chen YP et al (2020a) STING activator c-di-GMP-loaded mesoporous silica nanoparticles enhance immunotherapy against breast cancer. ACS Appl Mater Interfaces 12(51):56741–56752

Chen Y et al (2020b) Enhancement of antitumor efficacy of paclitaxel-loaded pegylated liposomes by n, n-dimethyl tertiary amino moiety in pancreatic cancer. Drug des Dev Ther 14:2945–2957

Chen C et al (2023a) Combination of a STING agonist and photothermal therapy using chitosan hydrogels for cancer immunotherapy. Biomacromol 24(6):2790–2803

Chen C et al (2023b) Development of a risk model to predict prognosis in breast cancer based on cGAS-STING-related genes. Front Genet 14:1121018

Chen S et al (2023c) Nanomedicines targeting activation of STING to reshape tumor immune microenvironment and enhance immunotherapeutic efficacy. Front Oncol 12:1093240

Chen X et al (2023d) Chemically programmed STING-activating nanoliposomal vesicles improve anticancer immunity. Nat Commun 14(1):4584

Chen J et al (2023e) Manganese-CpG nanocomposite integrates ROS-induced cell apoptosis and STING-activated and adjuvant-augmented immune responses for tumor elimination and prevention. Adv Ther 6(3):2200175

Chen X et al (2023f) A DNA/DMXAA/metal–organic framework activator of innate immunity for boosting anticancer immunity. Adv Mater 35(15):221044

Chen M et al (2024) cGAS-STING pathway expression correlates with genomic instability and immune cell infiltration in breast cancer. NPJ Breast Cancer 10(1):1

Cheng N et al (2018) A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1–insensitive models of triple-negative breast cancer. JCI Insight 3(22):e120638

Cheng H et al (2020) Activation of STING by cGAMP Regulates MDSCs to suppress tumor metastasis via reversing epithelial-mesenchymal transition. Front Oncol 10:896

Cheng N et al (2018) A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1-insensitive models of triple-negative breast cancer. JCI Insight 3(22)

Chintamaneni PK, Krishnamurthy PT, Pindiprolu SKSS (2021) polysorbate-80 surface modified nano-stearylamine BQCA conjugate for the management of Alzheimer's disease. RSC Adv 11(10):5325–5334

Chintamaneni PK, Krishnamurthy PT, Pindiprolu SKSS (2021) Polysorbate-80 surface modified nano-stearylamine BQCA conjugate for the management of Alzheimer's disease. RSC Adv 11(10):5325–34

Chintamaneni PK et al (2022) Engineered upconversion nanocarriers for synergistic breast cancer imaging and therapy: Current state of art. J Control Release 352:652–672

Chung SY et al (2023) A G-quadruplex stabilizer, CX-5461 combined with two immune checkpoint inhibitors enhances in vivo therapeutic efficacy by increasing PD-L1 expression in colorectal cancer. Neoplasia (United States) 35:100856

Constanzo J et al (2021) Radiation-induced immunity and toxicities: the versatility of the cGAS-STING pathway. Front Immunol 12:680503

Corrales L et al (2016) The host STING pathway at the interface of cancer and immunity. J Clin Investig 126(7):2404–2411

Crunkhorn S (2020) Strengthening the sting of immunotherapy. Nat Rev Immunol 20(10):589

Dalton WB, Ghiaur G, Resar LMS (2022) Taking the STING out of acute myeloid leukemia through macrophage-mediated phagocytosis. J Clin Invest 132(5)

Dane EL et al (2022) STING agonist delivery by tumour-penetrating PEG-lipid nanodiscs primes robust anticancer immunity. Nat Mater 21(6):710–720

de Moura Rodrigues D et al (2022) STING Targeting in Lung Diseases. Cells 11(21):3483

Delivery of stimulator of interferon genes (STING) (2021) agonist using polypeptide-modified dendrimer nanoparticles in the treatment of melanoma - Dosta - Advanced NanoBiomed Research - Wiley Online Library

Dong W et al (2023) Remodeling of tumor microenvironment by nanozyme combined cGAS–STING signaling pathway agonist for enhancing cancer immunotherapy. Int J Mol Sci 24(18):13935

Dorman K et al (2023) Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IFN-γ, TNF-α and PD-1/PD-L1 in comparison to established serum tumor markers. J Cancer Res Clin Oncol 149(6):2463–2474

Doshi AS et al (2022) Systemic nano-delivery of low-dose STING agonist targeted to CD103+ dendritic cells for cancer immunotherapy. J Control Release 345:721–733

Dosta P et al (2023) Investigation of the enhanced antitumour potency of STING agonist after conjugation to polymer nanoparticles. Nat Nanotechnol 18(11):1351–1363

Dosta P et al (2022) Conjugated STING-agonist nanoparticles enhance antitumor immunity in multiple tumor models

Du SS et al (2022) Radiation therapy promotes hepatocellular carcinoma immune cloaking via PD-L1 upregulation induced by cGAS-STING activation. Int J Radiat Oncol Biol Phys 112(5):1243–1255

Elmahboub YSM, Elkordy AA (2024) Polymeric nanoparticles: a promising strategy for treatment of Alzheimer's disease. J Taibah Univ Med Sci 19(3):549–565

UNCORRECTED PROOF

Lu X et al (2020) Engineered PLGA microparticles for long-term, pulsatile release of STING agonist for cancer immunotherapy. Sci Transl Med 12(556):eaaz6606

Lu X et al (2023) Encapsulation of STING agonist cGAMP with folic acid-conjugated liposomes significantly enhances antitumor pharmacodynamic effect. Cancer Biother Radiopharm 38(8):543–557

Lu D et al (2024) STING Agonist delivered by neutrophil membrane-coated gold nanoparticles exerts synergistic tumor inhibition with radiotherapy. ACS Appl Mater Interfaces 16(40):53474–88

Luo T et al (2024) STING agonist-conjugated metal-organic framework induces artificial leukocytoid structures and immune hotspots for systemic antitumor responses. Natl Sci Rev 11(7):nwae167

Mahin J et al (2024) cGAS/STING in skin melanoma: from molecular mechanisms to therapeutics. Cell Commun Signal 22(1):553

Marinello J et al (2022) Topoisomerase I poison-triggered immune gene activation is markedly reduced in human small-cell lung cancers by impairment of the cGAS/STING pathway. Br J Cancer 127(7):1214–1225

Meng Z et al (2022) Nanovaccines with cell-derived components for cancer immunotherapy. Adv Drug Deliv Rev 182:114107

Meric-Bernstam F et al (2019) Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas. Am Soc Clin Oncol

Miller G (2002) Drug targeting: breaking down barriers. Sci 297(5584):1116–1118

Mohseni G et al (2021) The function of cGAS-STING pathway in treatment of pancreatic cancer. Front Immunol 12:781032

Moore E et al (2016) Established T cell-inflamed tumors rejected after adaptive resistance was reversed by combination STING activation and PD-1 pathway blockade. Cancer Immunol Res 4(12):1061–1071

Moreira DA et al (2023) Dendrimers and derivatives as multifunctional nanotherapeutics for Alzheimer's disease. Pharmaceutics 15(4):1054

Nakajima S et al (2023) The impact of tumor cell-intrinsic expression of cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) on the infiltration of CD8+ T cells and clinical outcomes in mismatch repair proficient/microsatellite stable colorectal cancer. Cancers 15(10):2826

Nakamura T et al (2015) Liposomes loaded with a STING pathway ligand, cyclic di-GMP, enhance cancer immunotherapy against metastatic melanoma. J Control Release 216:149–157

Nakamura T et al (2021) STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation. J Immunother Cancer 9(7):e002852

Nday CM et al (2015) Quercetin encapsulation in modified silica nanoparticles: potential use against Cu(II)-induced oxidative stress in neurodegeneration. J Inorg Biochem 145:51–64

Nguyen DC et al (2024) Mannosylated STING agonist drugamers for dendritic cell-mediated cancer immunotherapy. ACS Cent Sci 10(3):666–675

Ohkuri T et al (2015) Protective role of STING against gliomagenesis: rational use of STING agonist in anti-glioma immunotherapy. OncoImmunology 4(4):e999523

Pépin G, Gantier MP (2017) cGAS-STING activation in the tumor microenvironment and its role in cancer immunity, in Advances in experimental medicine and biology 175–194

Perets N et al (2019) Golden exosomes selectively target brain pathologies in neurodegenerative and neurodevelopmental disorders. Nano Lett 19(6):3422–3431

Pindiprolu SKSS et al (2018) Nanocarrier based approaches for targeting breast cancer stem cells. Artif Cells Nanomed Biotechnol 46(5):885–98

Pindiprolu SKSS, Avasarala H, Dinakaran SK (2021a) Phenylboronic acid modified lipid nanocarriers mediated co-delivery of immunocytokine TRAIL and gamma-secretase inhibitor to triple negative breast cancer cells and cancer stem cells. Med Hypotheses 157:110716

Pindiprolu SKSS et al (2021b) DR5 antibody conjugated lipid-based nanocarriers of gamma-secretase inhibitor for the treatment of triple negative breast cancer. Chem Phys Lipids 235:105033

Rajak P, Nath LK, Bhuyan B (2023) pH switchable LLC nanoparticles targeting colon: optimization using D-optimal design. J Pharm Innov 18(1):128–43

Seneff S et al (2022) Innate immune suppression by SARS-CoV-2 mRNA vaccinations: the role of G-quadruplexes, exosomes, and microRNAs. Food Chem Toxicol 164:113008

Shae D et al (2019) Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy. Nat Nanotechnol 14(3):269–278

Shidhaye S et al (2008) Nanogel engineered polymeric micelles for drug delivery. Curr Drug Ther 3(3):209–217

Singh MK et al (2019) Tumor homing peptide modified liposomes of capecitabine for improved apoptotic activity and HER2 targeted therapy in breast cancer: in vitro studies. RSC Adv 9(43):24987–94

Smith TT et al (2017) Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors. J Clin Investig 127(6):2176–2191

Smith PL et al (2021) Effect of gemcitabine based chemotherapy on the immunogenicity of pancreatic tumour cells and T-cells. Clin Transl Oncol 23(1):110–121

Sokolowska O et al (2023) Immune checkpoint inhibition improves antimyeloma activity of bortezomib and STING agonist combination in Vk*MYC preclinical model. Clin Exp Med 23(5):1563–1572

Su T et al (2022) Responsive multivesicular polymeric nanovaccines that codeliver STING agonists and neoantigens for combination tumor immunotherapy. Advanced Science 9(23):2201895

Sun R et al (2020) A pilot study of urinary exosomes in Alzheimer's disease. Neurodegener Dis 19(5–6):184–191

Sun X et al (2021a) Amplifying STING activation by cyclic dinucleotide–manganese particles for local and systemic cancer metalloimmunotherapy. Nat Nanotechnol 16(11):1260–1270

Sun Y et al (2021b) Recent advances in Cu(II)/Cu(I)-MOFs based nano-platforms for developing new nano-medicines. J Inorg Biochem 225:111599

Sun Y et al (2023) Macrophage STING signaling promotes NK cell to suppress colorectal cancer liver metastasis via 4–1BBL/4–1BB co-stimulation. J ImmunoTher Cancer 11(3)

Talib WH et al (2022) Flavonoid-based nanomedicines to target tumor microenvironment. OpenNano 8:100081

Tang X et al (2024) Exosomes: the endogenous nanomaterials packed with potential for diagnosis and treatment of neurologic disorders. Colloids Surfaces B: Biointerfaces 239

Tao H et al (2023) cGAS-STING pathway activation and systemic anti-tumor immunity induction via photodynamic nanoparticles with potent toxic platinum DNA intercalator against uveal melanoma. Advanced Science 10(33):2302895

Targeted Delivery of Low-Dose Liposomal (n.d.) STING Agonist to CD103+ Dendritic Cells in Tumor Immunotherapy - ProQuest.

Tian X et al (2022) Medicinal chemistry perspective on cGAS-STING signaling pathway with small molecule inhibitors. Eur J Med Chem 244:114791

Tolg C et al (2023) RHAMM regulates MMTV-PyMT-induced lung metastasis by connecting STING-dependent DNA damage sensing to interferon/STAT1 pro-apoptosis signaling. Breast Cancer Res 25(1):74

UNCORRECTED PROOF